Stereotactic body radiotherapy (SBRT) alone achieves a 69.7% pooled 1- or 2-year systemic therapy-free survival rate across cancer types, with the highest rates seen in renal cell and prostate cancers ...
The RECIST guidelines provide a standardized approach for evaluating the response of cancer to treatment, allowing for consistent comparison of treatment efficacy across different therapies and ...
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma) Between March 19, 2019, and February 13, 2023, 41 ...
Serial metastasis-directed radiotherapy extended time off systemic therapy while maintaining favorable progression-free and overall survival in patients with oligometastatic clear-cell renal cell ...
—Building off of earlier findings, researchers sought to determine rates of neoadjuvant systemic therapy (NST) among U.S. women with cT1–2 N0 M0 HER2-positive breast cancer and identify factors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results